The SEC said Goldfield traded in MedImmune stock and call options more than 30 times in the six weeks leading up to AstraZeneca's April 23, 2007, announcement that it would buy MedImmune for $58 per share.
It said Goldfield did the trading while receiving material, nonpublic information about the sale process from his friend and co-defendant James Self, 45, a director of business development at a New Jersey-based pharmaceutical company.
Goldfield lives in Odessa, Florida, and Self lives in Doylestown, Pennsylvania, the SEC said in the complaint.
It was not immediately clear whether the defendants have retained counsel. Calls to phone numbers listed for the men were not immediately returned.
The case is SEC v. Self et al, U.S. District Court, Eastern District of Pennsylvania, No. 10-04430.
(Reporting by Jonathan Stempel; editing by John Wallace)
(c) Reuters 2012. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
